ResearcherQueen Mary University of LondonActive in the last 2 years

Zuoyi Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-3133-4152. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2025: 1 paper

Papers 1

The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells Against Pancreatic Cancer in an Immunocom… Co-author DOI 10.3390/cancers17091534 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Renato B. Baleeiro · 1 shared paper, 2025 · strength 0.26
- Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534 ↗
Lauren C. Cutmore · 1 shared paper, 2025 · strength 0.26
- Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534 ↗
Nicholas Fraser Brown · 1 shared paper, 2025 · strength 0.26
- Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534 ↗
Louisa S. Chard Dunmall · 1 shared paper, 2025 · strength 0.26
- Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534 ↗
Yaohe Wang · 1 shared paper, 2025 · strength 0.26
- Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534 ↗
John F. Marshall · 1 shared paper, 2025 · strength 0.26
- Paper The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells A… DOI 10.3390/cancers17091534 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.